openPR Logo
Press release

Cardiovascular Drugs Market Detailed Description by 2021

Cardiovascular Drugs Market Detailed Description by 2021

Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system. Some of the most common cardiovascular diseases are hypertensive heart disease, rheumatic heart disease, cerebrovascular heart disease, ischemic heart disease and inflammatory heart disease. Hypertensive heart disease occurs due to high blood pressure. Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina. Rheumatic heart disease is caused by rheumatic fever. Rheumatic fever occurs by preceding group A streptococcal infection. It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries. Cerebrovascular disease affects blood vessels of the brain. Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA). Ischemic heart disease is characterized by reduced blood supply to the heart. It is one of the most common causes of death in western parts of the world. Inflammatory heart disease occurs due to the infection of bacteria and virus. This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3776

The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs. Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL. Anti-dyslipidemics drug segment includes Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive. Anti-thrombotics drug segment is further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis.

In terms of geographic, North America dominates the global cardiovascular drugs market. This is due to increased awareness about various heart diseases in the region. The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America. In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market. However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market. This is due to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia. In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region. Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.

In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market. Increasing aging population and rising number of life-style diseases are also contributing in the growth of global cardiovascular drugs market. Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.

However, stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market. Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market. Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.

Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.

Request Report for TOC @ https://www.persistencemarketresearch.com/toc/3776

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cardiovascular Drugs Market Detailed Description by 2021 here

News-ID: 1127614 • Views: 127

More Releases from Persistence Market Research Pvt.Ltd.

Dental Restoration Market Present Scenario and the Growth Prospects 2017 - 2025
The term dental restoration covers an integrated management of oral health and restoring the oral health to a functional and esthetic state. The American Dental Association has not considered restorative dentist as a separate specialty though the dentists are able to perform man of these procedures without any additional course or certification. The dental restoration procedures depend on how difficult the procedure is and what the professional feels comfortable with.
Mobile Air Transfer Systems Market Trends and Key Developments 2017 - 2025
Mobile air transfer system is the system used in hospitals and other medical centers that helps to reduce patient handling injury. The system provides patients with simple and comfortable transfer experience along with significantly reducing the cumulative handling effect of thousands of pounds of patients’ weight while routine transfers. To ensure the safety of hundreds of millions of people suffering from health care associated infections and abnormalities mobile air transfer
Orthopedic Veterinary Implants Market is projected to reach US$ 3,500 Mn by 2026
Arthritis is a common disorder which has been recently seen spreading its roots dogs. At present, this diseases is treated with the help of orthopedic veterinary implants. The global orthopedic veterinary implants market has witnessed a substantial surge in the last couple years owing to the rise in pet adoption and their orthopedic surgeries. Majority of the population, especially in the developed regions, own pets such as cats or dogs.
Prepackaged Medical Kits and Trays Market is anticipated to Register a CAGR of 8 …
There has been a Herculean shift in the healthcare industry towards a reformed model and significant rise in investments worldwide is intended to improve various facilities and services across the healthcare industry. The concept of value-based pricing of pharmaceuticals has gained momentum in the last few years and a majority of the OECD countries have adopted this model. This shift has been a crucial component for the revenue growth of

All 5 Releases


More Releases for Cardiovascular

Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Market Overview of Cardiovascular Disease Industry 2018
Albany, NY, 3rd January : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" globally. The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1313843 The most crucial risk
Medpace Implements Digisonics Solution for Cardiovascular Research
Medpace, a clinical research lab in Cincinnati, has implemented the Digisonics CVIS system for their latest cardiovascular research study. Digisonics provides Medpace’s researchers with unparalleled capabilities for image review and quantitation with over 1,100 preset measurements and an unlimited number of user defined fields as well as the ability to quickly document their findings in a comprehensive report. An additional remote reading application, DigiNet Pro, provides Medpace’s multiple users
Cardiovascular Stents Market — Trends, 2017–2025
When a coronary artery is narrowed by the accumulation of fatty acids, also known as plaque, the blood flow to heart is reduced which result in the chest pain and if the blockage increases the blood flow to the heart is further reduced and might lead to cardiac arrest. To reduce the chances of heart attack, a tiny wire mesh tube is inserted in the artery with a balloon catheter,
Cardiovascular Information System Market
Rampant rise in incidence rate of cardiovascular diseases worldwide, is fueling demand for a system that can aid physicians in managing patient’s cardiovascular medical records. This cardiovascular information system is a web-based system that would allow easy report generation and distribution. The cardiovascular information system (CVIS) provides on-time access to cardiovascular electronic medical records (EMR) in images, reports, and waveforms. The prime benefit of cardiovascular information system is that the